AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3

AbCellera Biologics is evolving from a tech-enabled drug discovery partner to an integrated biotech with internal programs advancing through mid- to late-stage development. The company's platform has supported partner programs and a growing pipeline of internal programs. Its first internally developed drug, ABCL635, is in phase II trials for vasomotor symptoms and a readout is expected in Q3. AbCellera prioritizes programs based on scientific de-risking, unmet need and commercial opportunity, competitive advantage, and development path.